Innovative Technology for Enhanced Pharmaceutical and Medical Device Performance
July 9, 2025 - 02:57
Aptar today revealed its latest advancement in material science with the introduction of a dual-active technology designed to simultaneously manage moisture and oxygen levels. This innovative approach aims to enhance the stability and efficacy of pharmaceutical drugs and medical devices, addressing critical challenges in product preservation.
The new technology is expected to play a significant role in extending the shelf life of sensitive medications and formulations, which are often vulnerable to environmental factors. By effectively controlling moisture and oxygen, the dual-active material can help maintain the integrity of active ingredients, ensuring that they remain potent and effective throughout their intended use.
This development not only promises to improve the quality and safety of healthcare products but also aligns with the growing demand for more reliable and efficient packaging solutions in the pharmaceutical industry. As manufacturers seek to optimize their products, this technology stands out as a key innovation that could redefine standards in drug delivery and medical device performance.
MORE NEWS
August 9, 2026 - 18:31
County agenda features tax, technology and fairgroundsThe meeting will center on how to fund the ongoing fairgrounds project, a long-discussed priority for the county. Officials are expected to review the latest cost estimates and possible revenue...
August 9, 2026 - 00:24
‘AI slop’ crackdown: LinkedIn, Snap target low-quality gen-AI contentSocial platforms are starting to push back against the flood of generic, machine-generated posts, but they are doing so carefully. LinkedIn and Snap have both announced new measures aimed at...
August 8, 2026 - 05:47
Why GigaCloud Technology (GCT) Is Up 21.7% After Strong Q2 Results And New Buyback PlanGigaCloud Technology saw its stock surge 21.7% in early trading following the release of its second-quarter financial results and the announcement of a new capital return program. The company...
August 7, 2026 - 22:40
As FDA Approves First-Ever mRNA Flu Vaccine For Older Adults, Past KFF Polling Showed Most In This Age Group Were Uncertain About the Technology’s SafetyOn August 5, 2026, the U.S. Food and Drug Administration gave the green light to the first messenger RNA flu vaccine for adults aged 50 and older. The decision came after a clinical trial involving...